
Daiichi Sankyo rocked by further job losses
pharmafile | December 9, 2015 | Appointment | Manufacturing and Production | Daiichi, Daiichi Sankyo
The Japanese pharma firm Daiichi Sankyo is to close an antibody-producing subsidiary in Germany, as the company continues to cut jobs globally.
Daiichi is already shedding up to 1,200 jobs – or about half its workforce – in the US, and announced plans in March to lay off 16% of its workforce in the States in a series of redundancies at its base in Parsippany, New Jersey.
About 40 employees at U3 Pharma GmbH in Martinsried, Germany, will be affected, the company says in a statement.
“Daiichi Sankyo intends to strengthen its global research and development capabilities by increasing efficiency and streamlining processes. Based on this objective, the global R&D capacities have been reviewed and the Company has decided to concentrate core research functions of Daiichi Sankyo Group in future.
“U3, with about 40 employees and which is engaged in research and development work on antibody targeting for cancer treatments, will transfer its current research and development tasks to the Biologics Function in Tokyo.
Daiichi Sankyo says it will provide a more detailed update on the impact of this announcement on its FY2015 business results at a later date.
Related Content

AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

AstraZeneca shares results from phase 3 TROPION-Lung01 trial
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …






